Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
Merck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.
Last updated: 2026-11-20 20:36:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $133.47, with a market capitalization of $339.66B and a P/E ratio of 138.47. Over the past 52 weeks, its price has ranged from $93.90 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$339.66B | |
$134.33 | |
$137.13 | |
$132.33 | |
$132.81 | |
8.97M | |
9.72M | |
138.47 | |
$156.92 | |
$93.90 | |
2.46% | |
2026-09-30 |
Merck & Co., Inc. (MRK) is currently trading at $133.47 as of 2026-11-20 20:20:57, up 1.25% ($1.66) from the previous close of $132.81
During today's regular trading session, MRK has traded between $132.33 and $137.13, with a trading volume of 8.97M shares. The current price is near the lower end of today's range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $147.18 to $133.47, representing a decline of 9.32% ($13.71).
The stock traded between $131.36 and $149.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 8.32 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 62.8%
MRK is currently trading at $133.47, placing it 62.8% of the way from its 52-week low of $93.90 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75,000 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Merck & Co., Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Dec 15, 2026 |
| Payment Date | Jan 8, 2027 |
| Dividend Per Share | $0.88 |
Latest news related to Merck & Co., Inc. and MRK stock.
Merck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.
Six sectors are higher and five are lower in Friday's regular session, with defensive sectors holding two of the top three positions alongside Energy. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Sac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy in a
Both mRNA pioneers are transitioning beyond COVID-19 vaccine revenues. Moderna is recommended as the better buy due to growing sales, an advancing personalized cancer vaccine (intismeran) showing 42% risk reduction in melanoma trials, and an expanding vaccine portfolio. BioNTech, while having strong cash reserves and a promising pipeline, faces leadership transitions and more distant revenue opportunities.
AstraZeneca commits $200 million to Tempus AI in a master services agreement renewal through 2031, while William Blair maintains a Market Perform rating.
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC Stocks. Follow these three steps to open a Stocks account, transfer USDT, and place a Stocks order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MRK, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MRK shares and USD.
MRK Shares to USD
1.00 MRK shares = 133.467 USD
Calculations are estimates based on the latest available price and are for reference only.